



Published in final edited form as:

*Pediatr Diabetes*. 2018 October ; 19(Suppl 27): 7–19. doi:10.1111/pedi.12773.

## ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents

Elizabeth J. Mayer-Davis<sup>1,2</sup>, Anna R. Kahkoska<sup>1,2</sup>, Craig Jefferies<sup>3</sup>, Dana Dabelea<sup>4</sup>, Naby Balde<sup>5</sup>, Chun X. Gong<sup>6</sup>, Pablo Aschner<sup>7</sup>, Maria E. Craig<sup>8,9</sup>

<sup>1</sup>Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

<sup>2</sup>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

<sup>3</sup>Starship Children's Hospital, Auckland District Health Board, Auckland, New Zealand

<sup>4</sup>Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, Colorado

<sup>5</sup>Department of Endocrinology, University Hospital, Conakry, Guinea

<sup>6</sup>Beijing Children's Hospital, Capital Medical University, Beijing, China

<sup>7</sup>Colombian Diabetes Association, Bogotá, Colombia

<sup>8</sup>The Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia

<sup>9</sup>School of Women's and Children's Health, University of NSW, Sydney, New South Wales, Australia

### 1 | WHAT'S NEW?

- Emerging evidence suggests that trends in the incidence of type 1 diabetes varies markedly country-to-country.
- Recent genome wide association and whole genome/exome sequencing studies have increased clinical understanding of monogenic forms of diabetes that are distinct from the major classes of type 1 and type 2 diabetes.
- Based on key gene variants associated with type 1 diabetes, composite type 1 diabetes genetic risk scores have also been explored as novel tools to differentiate type 1 diabetes from monogenic diabetes and type 2 diabetes.

### 2 | RECOMMENDATIONS

- Diagnostic criteria for all types of diabetes in children and adolescents are based on laboratory measurement of plasma blood glucose levels (BGL) and the presence or absence of symptoms (**E**). Finger prick BGL testing should not be used to diagnose diabetes (**E**). A marked elevation of the BGL confirms the diagnosis of diabetes, including a random plasma glucose concentration  $\geq 11.1$  mmol/L (200 mg/dL) or fasting plasma glucose  $\geq 7.0$  mmol/L ( $\geq 126$  mg/dL) in the presence of overt symptoms.

**Correspondence:** Elizabeth J. Mayer-Davis, PhD, Cary C Boshamer Distinguished Professor of Nutrition and Medicine, Chair, Department of Nutrition, The University of North Carolina, 245 Rosenau Drive, Chapel Hill, NC 27599. mayerdav@email.unc.edu.

- If significant ketones are present in blood or urine, treatment is urgent, and the child should be referred to a diabetes specialist on the same day to avoid the development of ketoacidosis (**A**).
- The diagnosis of diabetes should not be based on a single plasma BGL in the absence of overt symptoms. If the diagnosis is in doubt, continued observation with fasting and/or 2 hour postprandial BGLs and/or an oral glucose tolerance test (OGTT) may be required (**E**). However, an OGTT is not needed and should not be performed if diabetes can be diagnosed using fasting, random, or postprandial criteria as excessive hyperglycemia can result (**E**).
- Hyperglycemia detected under conditions of stress, such as acute infection, trauma, surgery, respiratory distress, circulatory, or other stress may be transitory and requires treatment but should not in itself be regarded as diagnostic of diabetes (**E**).
- The possibility of other types of diabetes should be considered in the child who has negative diabetes-associated autoantibodies and (**B**):
  - an autosomal dominant family history of diabetes (maturity-onset diabetes of the young [MODY])
  - age less than 12 months and especially in first 6 months of life (NDM [neonatal diabetes mellitus])
  - mild-fasting hyperglycemia (5.5–8.5 mmol [100–150 mg/dL]), especially if young, non-obese, and asymptomatic
  - a prolonged honeymoon period over 1 year or an unusually low requirement for insulin of 0.5 U/kg/day after 1 year of diabetes
  - associated conditions such as deafness, optic atrophy, or syndromic features (mitochondrial disease)
  - a history of exposure to drugs known to be toxic to  $\beta$ -cells or cause insulin resistance (eg, immunosuppressive drugs such as tacrolimus or cyclosporin; glucocorticoids or some antidepressants).<sup>1</sup>
- The differentiation between type 1, type 2, monogenic, and other forms of diabetes has important implications for both treatment and education (**E**). Diagnostic tools, which may assist in confirming the diabetes type if the diagnosis is unclear, include:
  - Diabetes-associated autoantibodies: glutamic acid decarboxylase 65 autoantibodies (GAD); Tyrosine phosphatase-like insulinoma antigen 2 (IA2); insulin autoantibodies (IAA); and  $\beta$ -cell-specific zinc transporter 8 autoantibodies (ZnT8). The presence of one of more of these antibodies confirms the diagnosis of type 1 diabetes (**A**).
- Molecular genetic testing can help define the diagnosis and treatment of children with suspected monogenic diabetes and should be limited to those who on clinical grounds are likely to be positive (**E**).

### 3 | DEFINITION AND DESCRIPTION

The term *diabetes mellitus* describes a complex metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Inadequate insulin secretion and/or diminished tissue responses to insulin in the complex pathways of hormone action result in deficient insulin action on target tissues, which leads to abnormalities of carbohydrate, fat, and protein metabolism. Impaired insulin secretion and/or action may coexist in the same patient.<sup>2,3</sup>

While the etiology of diabetes is heterogeneous, most cases of diabetes can be classified into two broad etiopathogenetic categories (discussed later in further detail): type 1 diabetes, which is characterized primarily by deficiency of insulin secretion; or type 2 diabetes, which results from a combination of resistance to insulin action, as well as an inadequate compensatory insulin secretory response for the degree of insulin resistance. While type 1 diabetes remains the most common form of diabetes in young people in many populations, especially those of European background, type 2 diabetes has become an increasingly important public health concern globally among children in high risk ethnic populations as well as in those with severe obesity,<sup>4,5</sup> see ISPAD guideline on type 2 diabetes.<sup>6</sup>

### 4 | DIAGNOSTIC CRITERIA FOR DIABETES IN CHILDHOOD AND ADOLESCENCE

Diagnostic criteria for diabetes are based on blood glucose measurements and the presence or absence of symptoms.<sup>2,7</sup> Different methods can be used to diagnose diabetes (Table 1) and in the absence of unequivocal hyperglycemia, diagnosis must be confirmed by repeat testing.

- Diabetes in young people usually presents with characteristic symptoms such as polyuria, polydipsia, nocturia, enuresis, weight loss—which may be accompanied by polyphagia, behavioral disturbance including reduced school performance, and blurred vision. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia.
- In its most severe form, ketoacidosis or (rarer) non-ketotic hyperosmolar syndrome may develop and lead to stupor, coma and in the absence of effective treatment, death.
- If symptoms are present, measurement of glucose and ketones using a bedside glucometer, or urinary “dipstick” testing for glycosuria and ketonuria (if the fanner are not available) provides a simple and sensitive screening tool. If the BGL is elevated, then prompt referral to a center or facility with experience in managing children with diabetes is essential. Waiting another day specifically to confirm the hyperglycemia is unnecessary and if ketones are present in blood or urine, treatment is urgent, because ketoacidosis can evolve rapidly.
- A formal plasma glucose measurement is required to confirm the diagnosis; this should be based on laboratory glucose oxidase estimation rather than a capillary

blood glucose monitor. See Table 1 for fasting vs non-fasting blood glucose diagnostic cut-points.

- Scenarios where the diagnosis of diabetes may be unclear include:
- Absence of symptoms, for example, hyperglycemia detected incidentally or in children participating in screening studies
- Presence of mild/atypical symptoms of diabetes
- Hyperglycemia detected under conditions of acute infectious, traumatic, circulatory, or other stress, which may be transitory and should not be regarded as diagnostic of diabetes.

In these situations, the diagnosis of diabetes should not be based on a single plasma glucose concentration and continued observation with fasting and 2-hour postprandial BGL and/or an oral glucose tolerance test (OGTT may be required to confirm the diagnosis.

- An OGTT is not required and should not be performed if diabetes can be diagnosed using fasting, random, or postprandial criteria, as excessive hyperglycemia can result from the test. It is rarely indicated in making the diagnosis of type 1 diabetes in childhood and adolescence but may be useful in diagnosing other forms such as type 2 diabetes, monogenic diabetes, or cystic fibrosis-related diabetes (CFRD). If doubt remains, periodic OGTT retesting should be undertaken until the diagnosis is established.

Glycated hemoglobin (HbA1c) can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardized to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement.<sup>3,8</sup> Moreover, the validity of HbA1c as a measure of average glucose is complicated in the context of hemoglobinopathies, certain forms of anemia, or any other condition that affects normal red blood cell turnover. These conditions may follow specific ethnic and geographic distributions and thus is a critical consideration in areas of iron deficiency and anemia such as China, where diabetes prevalence estimates using HbA1c may result in underestimations among women with iron deficiency and overestimations in men with anemia<sup>9</sup> For conditions with abnormal red cell turnover, such as anemias from hemolysis and iron deficiency, as well as cystic fibrosis, the diagnosis of diabetes must employ glucose criteria exclusively.<sup>3,10</sup> In at-risk cohort studies, however, a rise in HbA1c within the normal range is frequently observed among individuals who subsequently progress to type 1 diabetes.<sup>11</sup>

## 5 | IMPAIRED GLUCOSE TOLERANCE AND IMPAIRED FASTING GLUCOSE

Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG)<sup>3</sup> are intermediate stages in the natural history of disordered carbohydrate metabolism between normal glucose homeostasis and diabetes. IFG and IGT are not interchangeable and represent different abnormalities of glucose regulation or different stages in the progression of dysglycemia. IFG is a measure of disturbed carbohydrate metabolism in the basal state while IGT is a dynamic measure of carbohydrate intolerance after a standardized glucose load. IFG and

IGT are not clinical entities in their own right; patients with IFG and/or IGT are referred to as having “prediabetes” indicating their relatively high risk for development of diabetes and cardiovascular disease, especially in the context of obesity.<sup>12</sup> Diagnostic criteria for prediabetes and diabetes in children, including fasting plasma glucose (FPG), OGTT, and HbA1c 5.7% to 6.4% (39–47 mmol/mol) have not been rigorously evaluated as they have in adults.<sup>13</sup>

IFG and IGT may be associated with the *metabolic syndrome*, the features of which include obesity (particularly abdominal or visceral obesity), dyslipidemia (high triglycerides and/or low-levels of high-density lipoproteins), and hypertension. IFG and IGT can be observed as intermediate stages in any of the disease processes listed in Table 2 (etiologic classification of diabetes) but are considered core defects typically associated with type 2 diabetes pathogenesis.

Individuals who meet criteria for IGT or IFG may be euglycemic in their daily lives as shown by normal or near-normal HbA1c, and those with IGT may manifest hyperglycemia only when challenged with an OGTT.

Categories of FPG are defined as follows:

- FPG <5.6 mmol/L (100 mg/dL) = normal fasting glucose
- FPG 5.6–6.9 mmol/L (100–125 mg/dl) = IFG
- FPG 7.0 mmol/L (126 mg/dL) = provisional diagnosis of diabetes (the diagnosis must be confirmed, as described in Table 1)

The corresponding categories for IGT when the OGTT is used are as follows:

- 2 hour postload plasma glucose <7.8 mmol/L (140 mg/dL) = normal glucose tolerance
- 2 hour postload plasma glucose 7.8 to <11.1 mmol/L (140–200 mg/dl) = IGT
- 2 hour postload plasma glucose 11.1 mmol/L (200 mg/dL) = provisional diagnosis of diabetes (the diagnosis must be confirmed, as described above).

The FPG cut-point for diagnosing IFG has been controversial. In 2003, the American Diabetes Association (ADA) guideline lowered the FPG cut-point from 6.11 to 6.94 mmol/L (110–125 mg/dL) to 5.55 to 6.94 mmol/L (100–125 mg/dL) to increase the sensitivity of testing to identify subjects at risk for development of type 2 diabetes.<sup>14</sup> The lower cut-point has not been adopted internationally.<sup>2,15</sup> The lower cut-point increases the number of subjects labeled with IFG and shows unclear associations with clinical complications.<sup>16,17</sup> A meta-analysis that evaluated the risk of coronary cardiovascular disease (CVD) in association with different criterion of IFG found that the CVD risk was comparably elevated along with evidence that the CVD risk maybe confounded by the undetected impaired IGT or other cardiovascular risk factors.<sup>18</sup> A glucose load (ie, an OGTT) is recommended in the context of elevated FPG concentration to accurately assess their future risk for type 2 diabetes.<sup>19</sup>

## 6 | CLASSIFICATION OF DIABETES AND OTHER CATEGORIES OF GLUCOSE REGULATION

The type of diabetes assigned to a young person at diagnosis is typically based on their characteristics at presentation, however, increasingly the ability to make a clinical diagnosis has been hampered by factors including the increasing prevalence of overweight in young people with type 1 diabetes<sup>20,21</sup> and the presence of diabetic ketoacidosis in some young people at diagnosis of type 2 diabetes.<sup>22,23</sup> In addition, the presentation of a familial form of mild diabetes during adolescence should raise the suspicion of monogenic diabetes, which accounts for 1% to 4% of pediatric diabetes cases.<sup>24–27</sup>

The etiological classification of diabetes is shown in Table 2, which is based on the ADA classification.<sup>3</sup> Using the etiologic approach to classification of diabetes types in youth based on the 1997 ADA framework, the majority of youth in the US-based SEARCH for Diabetes in Youth Study fell into either the autoimmune plus insulin sensitivity (54.5%) or non-autoimmune plus insulin resistance categories (15.9%) consistent with traditional descriptions of type 1 or type 2 diabetes.<sup>28</sup> The remaining groups represented obesity superimposed on type 1 diabetes (autoimmune plus insulin resistance, 19.5%) or atypical forms of diabetes (non-autoimmune plus insulin sensitivity, 10.1%), which require further characterization, including genetic testing for specific monogenic defects.<sup>28</sup> As the prevalence of childhood obesity continues to increase in the general population and in youth with diabetes, great care must be taken to correctly differentiate diabetes type in the setting of obesity,<sup>29</sup> particularly with regards to youth with type 1 diabetes and antibody negative diabetes who show clinical signs of type 2 diabetes such as obesity and insulin resistance.<sup>30</sup>

Some forms, including specific drug-, hormone-, or toxin-induced forms of diabetes, are uncommonly observed in young people. In Africa and South Asia, atypical forms of diabetes may occur in older children, adolescents, and young adults. These include ketosis-prone atypical diabetes, malnutrition-related diabetes, and fibro-calculous pancreatic disease.<sup>31,32</sup>

After the initial step of diagnosing diabetes, the differentiation between type 1, type 2, monogenic, and other forms of diabetes has important implications for both therapeutic decisions and educational approaches. Diabetes-associated autoantibodies are an important diagnostic tool. The presence of GAD, IA2, IAA and/or ZnT8 confirms the diagnosis of type 1 diabetes, since one and usually more of these autoantibodies are present in >90% of individuals when fasting hyperglycemia is initially detected.<sup>33</sup>

The possibility of other types of diabetes should be considered in the child who has no autoantibodies and:

- an autosomal dominant family history of diabetes in three generations with onset before age 35 years.
- diabetes diagnosed in the first 12 months of life, especially the first 6 months (NDM).
- mild-fasting hyperglycemia (5.5–8.5 mmol [100–150 mg/dL]), that is, IFG, especially if young, non-obese, and asymptomatic.

- associated conditions such as deafness, optic atrophy, or syndromic features (mitochondrial disease).
- a history of exposure to drugs known to be toxic to  $\beta$ -cells (cyclosporine or tacrolimus)<sup>34</sup> or cause insulin resistance (glucocorticoids and certain antidepressants).<sup>35–37</sup>

Characteristic features of youth onset *type 1 diabetes* in comparison with *type 2 diabetes* and *monogenic diabetes* are shown in Table 3. Type 2 diabetes and monogenic diabetes are more completely discussed in the ISPAD guidelines on these conditions.<sup>6,38</sup>

Regardless of the type of diabetes, however, the child who presents with severe hyperglycemia, ketonemia, and metabolic derangements will require insulin therapy initially to reverse the metabolic abnormalities.

Individuals with any form of diabetes may or may not require insulin treatment at various stages of their disease. Such use of insulin does not, of itself, classify the diabetes type.

## 7 | PATHOGENESIS OF TYPE 1 DIABETES

Type 1 diabetes is characterized by chronic immune-mediated destruction of pancreatic  $\beta$ -cells, leading to partial, or in most cases, absolute insulin deficiency. The majority of cases (type 1A) result from autoimmune-mediated pancreatic  $\beta$ -cell destruction, which occurs at a variable rate, and becomes clinically symptomatic when approximately 90% of pancreatic  $\beta$ -cells are destroyed. New insights into youth at-risk for developing type 1 diabetes suggest that early disease is a continuum that progresses through distinct identifiable stages prior to clinical symptoms.<sup>39</sup> Youth progress through three stages at variable rates: stage 1 is characterized by the presence of  $\beta$ -cell autoimmunity with normoglycemia and a lack of clinical symptoms, which can last for months to many years, stage 2 progresses to dysglycemia but remains asymptomatic, and stage 3 is defined as the onset of symptomatic disease.<sup>39</sup> The phases of diabetes are discussed in chapter 3 (add ref).<sup>40</sup>

The etiology of type 1 diabetes is multifactorial; however, the specific roles for genetic susceptibility, environmental factors, the immune system, and  $\beta$ -cells in the pathogenic processes underlying type 1 diabetes remain unclear. Diabetes-associated autoantibodies, which are serological markers of  $\beta$ -cell autoimmunity, include GAD, IA2, IAA, and ZnT8.<sup>33</sup> The expression of these antibodies is age-dependent, with IAA and ZnT8 more commonly expressed in children aged <10 years, while GAD and IA-2 are associated with older age and GAD with female gender.<sup>41</sup> Autoantibodies can occur very early in life and the order of appearance has been related to *HLA-DR-DQ* genotype.<sup>42</sup>

Susceptibility to type 1 diabetes mellitus is determined by multiple genes. HLA genotype confers approximately 30% to 50% of risk<sup>39,43,44</sup>; in the Caucasian population, specific combinations of HLA DR and DQ alleles determine genetic susceptibility.<sup>45</sup> The highest-risk haplotypes are DRB1\*03:01-DQA1\*05:01-DQB1\*02:01 and DRB1\*04-DQA1\*03:01-DQB1\*03:02 (also expressed as DR3/DR4 or DQ2/DQ8 using the former serological designation). For individuals who are heterozygotes for the two highest risk HLA haplotypes (DR3/4), the odds ratio is 30 for development of islet autoimmunity and type 1 diabetes,<sup>46</sup>

however, <10% of those with HLA-conferred diabetes susceptibility genes progress to clinical disease.<sup>47</sup>

Haplotypes conferring protection from type 1 diabetes are DRB1\*15:01-DQA1\*01:02-DQB1\*06:02, DRB1\*14:01-DQA1\*01:01-DQB\*05:03, and DRB1\*07:01-DQA1\*02:01-DQB1\*03:03.<sup>46</sup>

The rising incidence of type 1 diabetes,<sup>48</sup> parallels a decrease in the relative contribution from the highest risk HLA genotype.<sup>39,49</sup> In particular, high-risk HLA genotypes have become less frequent over time in youth with type 1 diabetes in the United Kingdom,<sup>50</sup> in Finland,<sup>51</sup> and in non-Hispanic white (NHW) and Hispanic origin youth with type 1 diabetes in the United States<sup>52</sup>.

The remaining genetic risk for type 1 diabetes can be attributed to the other non-HLA genes or loci identified that contribute model to small effects on disease risk.<sup>53</sup> Genome-wide association studies (GWAS) have identified more than 60 risk loci.<sup>54</sup> Of these, the highest non-HLA genetic contribution arises from the *INS*, *PTPN22*, *CTLA4*, and *IL2RA* genes, all of which are involved in, or contribute to, immune regulation in the pancreatic  $\beta$ -cell.<sup>53</sup>

In general, individuals at increased risk of developing type 1 diabetes can be identified by a combination of diabetes-associated autoantibodies, genetic markers, intravenous glucose tolerance test (IVGTT), and/or OGTT.<sup>55–59</sup> Recent work has studied the use of a type 1 diabetes genetic risk score for distinguishing patients with type 1 diabetes vs other forms of monogenic diabetes.<sup>60</sup> A risk score generated from approximately 30 common genetic variants associated with type 1 diabetes has been shown to effectively discriminate monogenic diabetes from type 1 diabetes.<sup>60</sup> Similarly, risk scores have been used to predict adolescents who will require insulin therapy, a novel tool for classifying individuals with type 1 diabetes from those with type 2 diabetes when clinical features and autoimmune markers are equivocal.<sup>29</sup>

The environmental triggers (infective, nutritional, and/or chemical) which initiate pancreatic  $\beta$ -cell destruction remain largely unknown, but the process usually begins months to years before the manifestation of clinical symptoms.<sup>57,61,62</sup> Enterovirus infection during pregnancy, infancy, childhood, and adulthood has been associated with development of both islet autoimmunity and type 1 diabetes in many populations,<sup>63,64</sup> particularly when infection occurs early in childhood,<sup>65</sup> and enteroviruses have been detected in the islets of individuals with diabetes.<sup>66–68</sup> Congenital rubella syndrome has been linked to the subsequent development of type 1 diabetes.<sup>69</sup> There is a paucity of data to support the role of other viruses, such as CMV, Mumps, Influenza, Rotavirus, and HIN1 in the development of type 1 diabetes.

## 8 | EPIDEMIOLOGY OF TYPE 1 DIABETES

Overall, approximately 96 000 children under 15 years are estimated to develop type 1 diabetes annually worldwide.<sup>70</sup> Older epidemiological incidence studies define the “onset of type 1 diabetes” by the date of the first insulin injection because of the variable time



between the onset of symptoms and diagnosis,<sup>71</sup> while current guidelines define diabetes based on abnormal test results (as shown in Table 1).

In most western countries, type 1 diabetes accounts for over 90% of childhood and adolescent diabetes, while across the life span, type 1 diabetes accounts for 5% to 10% of individuals with diabetes. However, the incidence of type 1 diabetes vs type 2 diabetes may be different across populations with different distribution of age and race/ethnicity.<sup>5,72</sup> For example, the highest prevalence of type 1 diabetes in the United States was found among white youth and lowest in American Indian youth, with prevalence rates of 2.55 per 1000 (95% confidence interval [CI], 2.48–2.62) vs 0.35 per 1000 (95% CI, 0.26–0.47), respectively.<sup>72</sup> By contrast, the highest prevalence of type 2 diabetes has been reported among non-white youth, with prevalence rates of 1.20 per 1000 among American Indian youth (95% CI, 0.96–1.51); 1.06 per 1000 among black youth (95% CI, 0.93–1.22); 0.79 per 1000 among Hispanic youth (95% CI, 0.70–0.88) vs 0.17 per 1000 among white youth (95% CI, 0.15–0.20).<sup>72</sup> Interestingly, recent data on the incidence of childhood diabetes in the United States show while both types of diabetes are increasing, type 1 diabetes is increasing more rapidly among Hispanic youth compared to non-Hispanic white youth (4.2% vs 1.2%) and type 2 diabetes is increasing most rapidly among non-Hispanic black, Asians or Pacific Islander, and Native American youth compared to non-Hispanic white youth (6.3%, 8.5%, and 8.9%, vs 0.6%, respectively).

Type 1 diabetes incidence varies greatly between different countries, within countries, and between different ethnic populations, with the highest incidence rates observed in Finland?<sup>3</sup> Northern Europe,<sup>74–76</sup> and Canada.<sup>77</sup> There is an approximate 20-fold difference in the disease incidence among Caucasians living in Europe,<sup>47</sup> and incidence rates are correlated with the frequency of HLA susceptibility genes in the general population.<sup>78,79</sup> Of the estimated approximately 500 000 children living with type 1 diabetes worldwide, approximately 26% are from Europe, and 22% are from North America and the Caribbean region.<sup>70</sup> In Asia, the incidence of type 1 diabetes is very low; Japan approximately 2 per 100 000 person-years<sup>80</sup>; China (Shanghai) 3.1 per 100 000<sup>81</sup>; Taiwan approximately 5 per 100 000<sup>82</sup> and the type 1 diabetes in these countries has a different and unique HLA association compared with Caucasians.<sup>83–86</sup> In addition, there is a distinct slowly progressive form of type 1 diabetes in Japan, which represents approximately one-third of cases of type 1 diabetes.<sup>87,88</sup>

A seasonal variation in the presentation of new cases is well described, with the peak being in the winter months, whereas other reports demonstrate higher rates in warmer seasons<sup>81</sup> or variation from year to year.<sup>89–91</sup> In addition, development of islet autoimmunity also demonstrates seasonal variation, as does the association between month of birth and risk of type 1 diabetes.<sup>92,93</sup>

In stark contrast to most autoimmune disorders, which disproportionately affect females, gender differences in the incidence of type 1 diabetes are found in some, but not all, populations. However, a persistent male gender bias across countries is generally observed in older adolescents and young adults,<sup>91,94–96</sup>

An increase in incidence of type 1 diabetes has been observed globally in recent decades.<sup>5,48,73,75,81,82,89–91,97–107</sup> For example, overall unadjusted estimated incidence rates of type 1 diabetes was reported to have increased in the United States by 1.4% annually (from 19.5 cases per 100 000 youth per year in 2002–2003 to 21.7 cases per 100 000 youth per year in 2011–2012).<sup>5</sup> The incidence of type 1 diabetes in youth less than 15 years of age has increased by 4.36% between 1995 and 2010, increasing at an accelerated rate after 2006.<sup>108</sup> There are estimates of greater increase in developing countries or those undergoing economic transition in recent decades.<sup>48,101</sup> In some reports, there has been a disproportionately greater increase in those under the age of 5 years,<sup>48,109</sup> but not in others.<sup>5</sup>

There is evidence for a plateau in incidence in some countries in recent years,<sup>73,75,102,110,112</sup> as well as cyclical trends.<sup>113</sup> Taken together, such marked variation in incidence trends is consistent with an etiologic understanding of type 1 diabetes as a disease that involves environmental triggers acting with genetic susceptibility to initiate autoimmune destruction of pancreatic  $\beta$ -cells. Interestingly, the rising incidence of type 1 diabetes is associated with an increased proportion of individuals with moderate or low risk HLA genotypes in some populations,<sup>50,51,114</sup> suggesting an increasing role for environmental factors in the disease etiology.<sup>39</sup>

Familial aggregation accounts for approximately 10% of cases of type 1 diabetes,<sup>115</sup> but more than 20% when accounting for the extended family history<sup>116</sup>; however, there is no recognizable pattern of inheritance. The lifelong risk of diabetes to an identical twin of a patient with type 1 diabetes is <40%<sup>47,117</sup>; for a sibling the risk is approximately 4% by age 20 years<sup>118–119</sup> and 9.6% by age 60 years<sup>50</sup>; compared with 0.5% for the general population. The cumulative risk of diabetes by age 15 is greater in HLA-identical DR3-DQ2/DR4-DQ8 siblings (17% vs 6% in those sharing one haplotype or none).<sup>120</sup> The risk is also higher in siblings of probands diagnosed at younger age, paternal young-onset diabetes, male sex, and older parental age.<sup>118,120,121</sup>

Type 1 diabetes is 2 to 3 times more common in the offspring of diabetic men (3.6%–8.5%) compared with diabetic women (1.3%–3.6%).<sup>121–126</sup> The cumulative risk for type 1 diabetes is approximately 4% for offspring of adult onset (15–39 years) type 1 diabetes,<sup>127</sup> with a similar recurrence risk in the offspring of mothers and fathers.

## 9 | PATHOGENESIS OF TYPE 2 DIABETES

Type 2 diabetes mellitus (type 2 diabetes) is characterized by hyperglycemia caused by insulin resistance, and relative impairment in insulin secretion due to  $\beta$ -cell dysfunction either as an inborn genetic defect or acquired from glucose toxicity, lipotoxicity, or other mechanisms. The etiology includes contribution by genetic and physiologic components, lifestyle factors such as excess energy intake, insufficient physical activity, and increased sedentary behavior.<sup>4</sup> The pathogenesis of type 2 diabetes is variable between individuals and complicated by heterogeneity in the degree of insulin resistance and deficiency, genetic, and environmental influences, and comorbidities including hypertension, hyperlipidemia, and obesity.<sup>128</sup> Peripheral insulin resistance is a key feature that occurs early in the disease course, and initially is compensated by increased insulin secretion reflected in

hyperinsulinemia.<sup>128</sup> Sustained hyperglycemia over time results in  $\beta$ -cell exhaustion and declining insulin secretion (glucose toxicity).

Type 2 diabetes in youth is typically clinically characterized by insulin resistance, as well as other features of metabolic syndrome which are commonly present, including hypertension, hyperlipidemia, acanthosis nigricans, fatty liver disease, and polycystic ovary disease.<sup>3</sup>

## 10 | EPIDEMIOLOGY OF TYPE 2 DIABETES

Type 2 diabetes is becoming more common and accounts for a significant proportion of youth onset diabetes in certain at risk populations,<sup>6</sup> but population-based epidemiological data are more limited compared with type 1 diabetes. Variations in population characteristics and methodological dissimilarities between studies may also account for some of the variation in incidence trends.<sup>129</sup> Youth who are obese, of certain ethnic and genetic backgrounds, and having a positive family history of type 2 diabetes are at the highest risk for type 2 diabetes.

Worldwide incidence and prevalence of type 2 diabetes in children and adolescents vary substantially among countries, age categories and ethnic groups,<sup>129</sup> and the results of epidemiologic studies have shown the incidence of type 2 diabetes in children and adolescents to have a range of 1 to 51 per 1000.<sup>4</sup> The highest reported rate is for certain groups of 15- to 19-year-old North American Indians, where the prevalence of type 2 diabetes per 1000 was 50.9 for Pima Indians, (vs 4.5 for all US American Indians and 2.3 for Canadian Cree and Ojibway Indians in Manitoba).<sup>130</sup> Increasing incidence rates for type 2 diabetes in pediatric patients have been reported in the United States, Canada, Japan, Austria, United Kingdom, and Germany.<sup>131</sup> As in adults, youth with type 2 diabetes are more likely to be from lower socioeconomic backgrounds, where the sociodemographic disparities in disease seem to parallel the disparities in obesity among youth.<sup>132</sup>

Type 2 diabetes has increased dramatically in children and adolescents throughout the world in recent years,<sup>133,134</sup> particularly among youth of minority racial and ethnic groups.<sup>5,130</sup> The incidence of IFG and IGT has also increased, and are associated with age and degree of obesity among children<sup>12</sup> (See ISPAD Guidelines on Type 2 Diabetes.)

## 11 | MONOGENIC DIABETES

A familial form of mild, non-ketotic diabetes presenting during adolescence or early adulthood,<sup>135,136</sup> originally termed maturity-onset diabetes of the young (MODY), is now recognized as a group of disorders which result from dominantly acting heterozygous mutations in genes important for the development or function of  $\beta$ -cells.<sup>136,137</sup> Despite the classical description of MODY as a disorder with onset before 25 years of age, autosomal dominant inheritance, and non-ketotic diabetes mellitus,<sup>137,138</sup> it is clear that there is considerable overlap in the presentations of type 1 diabetes, type 2 diabetes, and monogenic diabetes, so that monogenic diabetes may be misdiagnosed and treated incorrectly. With the increased awareness of type 2 diabetes in young people, many such patients will meet all of the “classical” criteria for monogenic diabetes, but initially may be misclassified as having

type 2 diabetes.<sup>139</sup> Certain clinical characteristics should alert the clinician to the possibility of monogenic diabetes, as outlined in Table 3.

It is now considered more appropriate to define monogenic diabetes by its genetic subgroups, as shown in Table 2. The most common form is associated with mutations in the transcription factor hepatocyte nuclear factor (HNF)-1 $\alpha$  (also known as HNF1-MODY). Mutations in the glucokinase gene (*GCK*) and *HNF4A* contribute to the majority of remaining cases, while rare forms result from mutations in other transcription factors, including *HNF-1B*, pancreatic-duodenal homeobox (*PDX-1*), and *NeuroD1*<sup>137,140</sup>; for further detail see ISPAD guideline on Monogenic diabetes.<sup>38</sup>

Within the diagnostic groups of monogenic diabetes, there is great variation in the degree of hyperglycemia, need for insulin and risk for future complications; importantly, HNF4A-MODY and HNF1A-MODY can be successfully treated with oral sulfonylurea medication, at least initially, whereas GCK-MODY does not require active treatment except in the setting of pregnancy where an affected mother has an unaffected fetus and there is in utero evidence of macrosomia.<sup>141</sup>

Thus, making a specific molecular diagnosis permits one to predict the expected clinical course of the disease, guide the most appropriate management for an individual, has important implications for family members, and enables genetic counseling for future offspring and extended genetic testing in other diabetic family members, whose diabetes may eventually be reclassified.<sup>142</sup>

## 12 | NEONATAL DIABETES

Type 1 diabetes rarely presents in the first year of life, particularly before age 6 months,<sup>143,144</sup> and in very young infants is most likely to be due to mutations in the transcription factor *FOXP3* as part of the immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome.<sup>145</sup> A monogenic form of diabetes in the first 6 months of life is known NDM, although cases may present as late 9 to 12 months of age.<sup>146–148</sup> Further details of the genetic basis of NDM are provided in the ISPAD guideline on Monogenic Diabetes.<sup>38</sup>

## 13 | MITOCHONDRIAL DIABETES

Mitochondrial diabetes is commonly associated with sensorineural deafness and is characterized by progressive non-autoimmune  $\beta$ -cell failure.<sup>149,150</sup> Transmission of maternal mutated mitochondrial DNA (mtDNA) can result in maternally inherited diabetes. The most common mutation occurs at position 3243 in the tRNA leucine gene, leading to an A-to-G transition.<sup>151–152</sup> Mitochondrial diabetes may present with variable phenotypes, ranging from acute onset with or without ketoacidosis, to a more gradual onset resembling type 2 diabetes. The disease typically presents in young adults,<sup>149</sup> but can occur in children and adolescents, who have a lower prevalence of hearing loss compared with adults.<sup>153</sup>

## 14 | CYSTIC FIBROSIS-RELATED DIABETES

Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity associated with cystic fibrosis (CF). The pathophysiology of CFRD is primarily due to insulin deficiency, along with glucagon deficiency and variable insulin resistance (particularly during acute illness, secondary to infections and medications such as bronchodilators and glucocorticoids). Other contributory factors include the need for high caloric intake, delayed gastric emptying, altered intestinal motility, and liver disease.<sup>154</sup> CF is associated with a progressive deterioration in glucose tolerance as individuals grow older, including indeterminate glycemia followed by IGT and finally diabetes. Early CFRD is characterized by normal fasting glucose levels, but over time fasting hyperglycemia develops.

CFRD typically presents in adolescence and early adulthood,<sup>155</sup> but may occur at any age including infancy. The presentation may be asymptomatic, insidious, associated with poor weight gain,<sup>156</sup> or precipitated by insulin resistance associated with infection/use of glucocorticoids. Detection rates for CFRD vary with screening practices.<sup>157</sup> The onset of CFRD is defined as the date a person with CF first meets diabetes diagnostic criteria, even if hyperglycemia subsequently abates.

The onset of CFRD is a poor prognostic sign and is associated with increased morbidity and mortality reported prior to implementation of routine screening for CFRD and early use of insulin therapy.<sup>158</sup> Poorly controlled CFRD interferes with immune responses to infection and promotes protein catabolism.<sup>157,159</sup>

Annual screening for CFRD should commence by age 10 years in all CF patients who do not have CFRD. Screening should be performed using the 2-hour 75 g (1.75 g/kg) OGTT. A more comprehensive discussion on CFRD can be found in Chapter X.<sup>10</sup>

## 15 | HEMOCHROMATOSIS AND DIABETES

Hemochromatosis is an inherited or secondary disorder caused by excessive iron storage leading to multiple organ damage.<sup>160</sup> Primary hemochromatosis is an autosomal recessive disease presenting as liver cirrhosis, cardiac dysfunction, hypothyroidism, diabetes, and hypogonadism, while secondary hemochromatosis may develop in patients who have received multiple red blood cell transfusions.<sup>161</sup> Diabetes associated with hemochromatosis is primarily due to loss of insulin secretory capacity by damaged  $\beta$ -cells with insulin resistance playing a secondary role.<sup>162</sup> The prevalence of diabetes in this population is not well characterized and has likely been underestimated.<sup>162</sup>

## 16 | DIABETES INDUCED BY DRUGS AND TOXINS

A range of pharmacological agents impair insulin secretion (eg, propranolol), and/or action (eg, glucocorticoids, antipsychotic agents), while others (eg, pentamidine) can cause permanent  $\beta$ -cell damage.<sup>140,163,164</sup>

In neurosurgery, large doses of dexamethasone are frequently used to prevent cerebral edema. The additional stress of surgery may add to the drug-induced insulin resistance, and

cause a relative insulin deficiency, sufficient to cause transient diabetes. Hyperglycemia may be exacerbated if large volumes of intravenous dextrose are given for management of diabetes insipidus. An intravenous insulin infusion is the optimal method to control the hyperglycemia, which is usually transient.

In oncology, protocols which employ L-asparaginase, high dose glucocorticoids, cyclosporin, or tacrolimus (FK506) may be associated with secondary or transient diabetes. L-asparaginase usually causes a reversible form of diabetes.<sup>165</sup> Tacrolimus and cyclosporin may cause a permanent form of diabetes possibly due to islet cell destruction.<sup>34</sup> Often the diabetes is cyclical and associated with the chemotherapy cycles, especially if associated with large doses of glucocorticoids.

Following organ transplantation, diabetes most frequently occurs with the use of high dose glucocorticoids and tacrolimus; the risk is increased in patients with preexisting obesity.<sup>166–168</sup>

Diabetes can also be induced by the use of atypical antipsychotics including olanzapine, risperidol, quetiapine, and ziprasidone, which may be associated with weight gain. In children and adolescents, use of antipsychotics was associated with a more than 3-fold increased risk of non-autoimmune diabetes, and the risk was significantly higher with increasing cumulative dose.<sup>169</sup> Among Canadian youth with medication induced diabetes, risk factors for type 2 diabetes (family history of type 2 diabetes, obesity, non-Caucasian ethnicity, acanthosis nigricans) were less commonly observed than in youth with type 2 diabetes.<sup>170</sup>

## 17 | STRESS HYPERGLYCEMIA

Stress hyperglycemia has been reported in up to 5% of children presenting to an emergency department, in association with acute illness/sepsis; traumatic injuries, febrile seizures, burns, and elevated body temperature (>39°C).<sup>171–174</sup> However, the incidence of severe hyperglycemia (>16.7 mmol/L or 300 mg/dL) was <1% and almost two-thirds of patients had received glucose-influencing interventions before evaluation, suggesting the etiology may at least in part be iatrogenic.<sup>175</sup>

The reported incidence of progression to overt diabetes varies from 0% to 32%.<sup>174,176–181</sup> Children with incidental hyperglycemia without a serious concomitant illness were more likely to develop diabetes than those with a serious illness.<sup>179</sup> As would be expected, testing for diabetes associated autoantibodies had a high positive and negative predictive value for the development of type 1 diabetes in children with stress hyperglycemia.<sup>179</sup> In children who have sustained severe burns, insulin resistance may persist for up to 3 years later.<sup>173</sup>

## 18 | CONCLUSION

The worldwide trends of type 1 diabetes incidence vary by sex, by race, by age group as well as by time period around the world, consistent with disease etiology that involves environmental triggers superimposed on genetic susceptibility. Recent evidence has elucidated that presymptomatic type 1 diabetes progresses through a continuum of three

distinct identifiable stages prior to the onset of symptoms.<sup>39</sup> Moreover, recent GWAS and whole genome/exome sequencing studies have increased clinical understanding of monogenic forms of diabetes that are distinct from the major classes of type 1 and type 2 diabetes. Composite type 1 diabetes genetic risk scores have also been explored as novel tools to differentiate type 1 diabetes from monogenic diabetes and type 2 diabetes. The worldwide incidence of type 2 diabetes is increasing and represents a public health concern among children and young adults. Pathogenesis of type 2 diabetes is complex and further complicated by heterogeneity in genetic vs environmental input, comorbid metabolic disease. Other forms of diabetes are explored in detail in other chapters.

## REFERENCES

1. Repaske DR. Medication-induced diabetes mellitus. *Pediatr Diabetes*. 2016;17(6):392–397. [PubMed: 27492964]
2. World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva, Switzerland; 2006.
3. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. *Diabetes Care*. 2018;41(suppl 1):S13–S27. [PubMed: 29222373]
4. Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: epidemiology and treatment. *Curr Diab Rep*. 2014;14(8):508. [PubMed: 24919749]
5. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. *N Engl J Med*. 2017;376(15):1419–1429. [PubMed: 28402773]
6. Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes in the child and adolescent *Pediatr Diabetes*. 2014;5(suppl 20):26–46.
7. American Diabetes Association. Standards of medical care in diabetes--2014. *Diabetes Care*. 2014;37(suppl 1):S14–S80. [PubMed: 24357209]
8. WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva, Switzerland: World Health Organization. Copyright (c) World Health Organization 2011; 2011.
9. Attard S, Herring A, Wang H, et al. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. *Nutr Diabetes*. 2015;5(6):e166. [PubMed: 26098445]
10. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. ISPAD Clinical Practice Consensus Guidelines 2018 Compendium Management of cystic fibrosis related diabetes in children and adolescents. *Pediatr Diabetes*. 2018 10.1111/peidi.12732.
11. Helminen O, Aspholm S, Pokka T, et al. HbA1c predicts time to diagnosis of type 1 diabetes in children at risk. *Diabetes*. 2015;64(5): 1719–1727. [PubMed: 25524912]
12. Hagman E, Reinehr T, Kowalski J, Ekblom A, Marcus C, Holl R. Impaired fasting glucose prevalence in two nationwide cohorts of obese children and adolescents. *Int J Obes (Lond)*. 2014;38(1):40. [PubMed: 23828099]
13. American Diabetes Association. Professional Practice Committee: Standards of Medical Care in Diabetes—2018. Alexandria, Virginia: American Diabetes Association; 2018.
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2003;26(suppl 1):S5–S20. [PubMed: 12502614]
15. Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre--diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. *Diab Vasc Dis Res*. 2014;11(3):133–173. [PubMed: 24800783]
16. Huang Y, Cai X, Chen P, et al. Associations of prediabetes with all--cause and cardiovascular mortality: a meta-analysis. *Ann Med*. 2014; 46(8):684–692. [PubMed: 25230915]
17. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease. *J Am Coll Cardiol*. 2010;55(13):1310–1317. [PubMed: 20338491]

18. Xu T, Liu W, Cai X, et al. Risk of coronary heart disease in different criterion of impaired fasting glucose: a meta-analysis. *Medicine (Baltimore)*. 2015;94(40):e1740. [PubMed: 26448033]
19. Abdul-Ghani M, DeFronzo RA, Jayyousi A. Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter? *Curr Opin Clin Nutr Metab Care*. 2016;19(5):394–399. [PubMed: 27389083]
20. Islam ST, Abraham A, Donaghue KC, et al. Plateau of adiposity in Australian children diagnosed with type 1 diabetes: a 20-year study. *Diabet Med*. 2014;31:686–690. [PubMed: 24495260]
21. Kapellen TM, Gausche R, Dost A, et al. Children and adolescents with type 1 diabetes in Germany are more overweight than healthy controls: results comparing DPV database and CrescNet database. *J Pediatr Endocrinol Metab*. 2014;27(3–4):209–214. [PubMed: 24197766]
22. Rewers A, Klingensmith G, Davis C, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for diabetes in youth study. *Pediatrics*. 2008;121(5):e1258–e1266. [PubMed: 18450868]
23. Dabelea D, Rewers A, Stafford JM, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. *Pediatrics*. 2014;133(4):e938–e945. [PubMed: 24685959]
24. Fendler W, Borowiec M, Baranowska-Jazwiecka A, et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. *Diabetologia*. 2012;55(10):2631–2635. [PubMed: 22782286]
25. Irgens HU, Molnes J, Johansson BB, et al. Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry. *Diabetologia*. 2013;56(7):1512–1519. [PubMed: 23624530]
26. Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. *J Clin Endocrinol Metab*. 2013;98(10):4055–4062. [PubMed: 23771925]
27. Galler A, Stange T, Muller G, et al. Incidence of childhood diabetes in children aged less than 15 years and its clinical and metabolic characteristics at the time of diagnosis: data from the childhood diabetes registry of Saxony, Germany. *Horm Res Paediatr*. 2010;74(4):285–291. [PubMed: 20516654]
28. Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for diabetes in youth study. *Diabetes Care*. 2011;34(7):1628–1633. [PubMed: 21636800]
29. Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. *Diabetes Care*. 2016;39(3):337–344. [PubMed: 26577414]
30. Mottalib A, Kasetty M, Mar JY, Elseaidy T, Ashrafzadeh S, Hamdy O. Weight management in patients with type 1 diabetes and obesity. *Curr Diab Rep*. 2017;17(10):92. [PubMed: 28836234]
31. Gill GV, Mbanya JC, Ramaiya KL, Tesfaye S. A sub-Saharan African perspective of diabetes. *Diabetologia*. 2009;52(1):8–16. [PubMed: 18846363]
32. Bannan KK, Premalatha G, Mohan V. Tropical chronic pancreatitis. *Postgrad Med J*. 2003;79(937):606–615. [PubMed: 14654569]
33. Watkins RA, Evans-Molina C, Blum JS, Dimeglio LA. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. *Transl Res*. 2014;164:110–121. [PubMed: 24662515]
34. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. *Transplantation*. 1999;68(3):396–402. [PubMed: 10459544]
35. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. *Clin Sci*. 1999;96(5):513–523. [PubMed: 10209084]
36. Ferris HA, Kahn CR. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. *J Clin Invest*. 2012;122(11):3854–3857. [PubMed: 23093783]



37. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. *Expert Opin Drug Saf*. 2006;5(1):157–168. [PubMed: 16370964]
38. Hattersley AT, Greeley SA, Polak M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. *Pediatr Diabetes*. 10.1111/pedi.12772.
39. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care*. 2015;38(10): 1964–1974. [PubMed: 26404926]
40. Couper JJ, Hailer MJ, Greenbaum CJ, et al. ISPAD Clinical Practice Consensus Guidelines 2018 Stages of type 1 diabetes in children and adolescents. *Pediatric diabetes*. 2018 10.1111/pedi.12734.
41. Howson JM, Stevens H, Smyth DJ, et al. Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. *Diabetes*. 2011;60(10): 2635–2644. [PubMed: 21831970]
42. Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. *Diabetologia*. 2015;58(5):980–987. [PubMed: 25660258]
43. Noble JA, Valdes AM, Cook M, Klitz, Thomson G, Erlich HA The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. *Am J Hum Genet*. 1996;59(5):1134–1148. [PubMed: 8900244]
44. Lambert AP, Gillespie KM, Thomson G, et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. *J Clin Endocrinol Metab*. 2004;89(8):4037–4043. [PubMed: 15292346]
45. Nguyen C, Varney MD, Harrison LC, Morahan G. Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms. *Diabetes*. 2013;62(6):2135–2140. [PubMed: 23378606]
46. Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes*. 2008;57(4):1084–1092. [PubMed: 18252895]
47. Knip M. Pathogenesis of type 1 diabetes: implications for incidence trends. *Horm Res Paediatr*. 2011;76(suppl 1):57–64. [PubMed: 21778751]
48. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltész G, EURO-DIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. *Lancet*. 2009;373(9680): 2027–2033. [PubMed: 19481249]
49. Steck AK, Armstrong TK, Babu SR, Eisenbarth GS, Type 1 Diabetes Genetics Consortium. Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. *Diabetes*. 2011;60(3):1045–1049. [PubMed: 21307077]
50. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. *Lancet*. 2004;364(9446):1699–1700. [PubMed: 15530631]
51. Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes—indication of an increased environmental pressure? *Diabetologia*. 2003;46 (3):420–425. [PubMed: 12687342]
52. Vehik K, Hamman RF, Lezotte D, et al. Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. *Diabetes Care*. 2008;31(7):1392–1396. [PubMed: 18356404]
53. Sepe V, Loviselli A, Bottazzo GF. Genetics of type 1A diabetes. *N Engl J Med*. 2009;361(2):211.
54. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat Genet*. 2009;41(6):703–707. [PubMed: 19430480]
55. Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. *Proc Natl Acad Sci USA*. 2006;103(38):14074–14079. [PubMed: 16966600]

56. Steck AK, Wong R, Wagner B, et al. Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR, DQ genotypes. *Diabetes*. 2012;61(3):753–758. [PubMed: 22315323]
57. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA*. 2013;309(23):2473–2479. [PubMed: 23780460]
58. Bonifacio E, Krumsiek J, Winkler C, Theis FJ, Ziegler AG. A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. *Acta Diabetol*. 2014;51(3):403–411. [PubMed: 24249616]
59. DPT-1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. *N Engl J Med*. 2002;346(22):1685–1691. [PubMed: 12037147]
60. Patel KA, Oram RA, Flanagan SE, et al. Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. *Diabetes*. 2016;65(7):2094–2099. [PubMed: 27207547]
61. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. *Diabetes*. 1996;45(7):926–933. [PubMed: 8666144]
62. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial--type 1. *Diabetes Care*. 2005;28(5):1068–1076. [PubMed: 15855569]
63. Yeung G, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus - a systematic review of molecular studies. *BMJ*. 2011;342:d35. [PubMed: 21292721]
64. Laitinen OH, Honkanen H, Pakkanen O, et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. *Diabetes*. 2014;63(2):446–455. [PubMed: 23974921]
65. Mustonen N, Siljander H, Peet A, et al. Early childhood infections precede development of beta-cell autoimmunity and type 1 diabetes in children with HLA-conferred disease risk. *Pediatr Diabetes*. 2018; 19(2):293–299. [PubMed: 28597957]
66. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. *Diabetologia*. 2009;52(6): 1143–1151. [PubMed: 19266182]
67. Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. *Proc Natl Acad Sci USA*. 2007;104(12):5115–5120. [PubMed: 17360338]
68. Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. *Diabetologia*. 2013;56(1):185–193. [PubMed: 23064357]
69. Gale EA. Congenital rubella: citation virus or viral cause of type 1 diabetes? *Diabetologia*. 2008;51(9):1559–1566. [PubMed: 18641967]
70. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.
71. Diamond Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. *Diabet Med*. 2006;23(8):857–866. [PubMed: 16911623]
72. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. *JAMA*. 2014;311(17):1778–1786. [PubMed: 24794371]
73. Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. *JAMA*. 2013;310(4):427–428. [PubMed: 23917294]
74. Berhan Y, Waernbaum I, Lind T, Mollsten A, Dahlquist G, Swedish Childhood Diabetes Study Group. Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden. *Diabetes*. 2011;60(2): 577–581. [PubMed: 21270269]
75. Skrivarhaug T, Stene LC, Drivvoll AK, Strom H, Joner G, Norwegian Childhood Diabetes Study Group. Incidence of type 1 diabetes in Norway among children aged 0–14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian childhood diabetes registry. *Diabetologia*. 2014;57(1):57–62. [PubMed: 24149838]

76. Rawshani A, Landin-Olsson M, Svensson AM, et al. The incidence of diabetes among 0–34 year olds in Sweden: new data and better methods. *Diabetologia*. 2014;57:1375–1381. [PubMed: 24710965]
77. Newhook LA, Penney S, Fiander J, Dowden J. Recent incidence of type 1 diabetes mellitus in children 0–14 years in Newfoundland and Labrador, Canada climbs to over 45/100,000: a retrospective time trend study. *BMC Res Notes*. 2012;5:628. [PubMed: 23146327]
78. Ilonen J, Reijonen H, Green A, et al. Geographical differences within Finland in the frequency of HLA-DQ genotypes associated with type 1 diabetes susceptibility. *Eur J Immunogenet*. 2000;27(4):225–230.
79. Kukko M, Virtanen SM, Toivonen A, et al. Geographical variation in risk HLA-DQB1 genotypes for type 1 diabetes and signs of beta-cell autoimmunity in a high-incidence country. *Diabetes Care*. 2004;27(3): 676–681. [PubMed: 14988284]
80. Tajima N, Morimoto A. Epidemiology of childhood diabetes mellitus in Japan. *Pediatr Endocrinol Rev*. 2012;10(suppl 1):44–50. [PubMed: 23330245]
81. Zhao Z, Sun C, Wang C, et al. Rapidly rising incidence of childhood type 1 diabetes in Chinese population: epidemiology in Shanghai during 1997–2011. *Acta Diabetol*. 2014;51(6):947–953. [PubMed: 24777734]
82. Lin WH, Wang MC, Wang WM, et al. Incidence of and mortality from type I diabetes in Taiwan from 1999 through 2010: a nationwide cohort study. *PLoS One*. 2014;9(1):e86172. [PubMed: 24465941]
83. Park Y. Why is type 1 diabetes uncommon in Asia? *Ann N Y Acad Sci*. 2006;1079:31–40. [PubMed: 17130529]
84. Park YS, Wang CY, Ko KW, et al. Combinations of HLA DR and DQ molecules determine the susceptibility to insulin-dependent diabetes mellitus in Koreans. *Hum Immunol*. 1998;59(12):794–801. [PubMed: 9831135]
85. Ikegami HIRO, Fujisawa TOMO, Kawabata YUMI, Noso SHIN, Ogihara TOSH. Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations. *Ann N Y Acad Sci*. 2006;1079(1):51–59. [PubMed: 17130532]
86. Sugihara S. Genetic susceptibility of childhood type 1 diabetes mellitus in Japan. *Pediatr Endocrinol Rev*. 2012;10(suppl1):62–71. [PubMed: 23330247]
87. Urakami T, Suzuki J, Yoshida A, Saito H, Mugishima H. Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area. *Diabetes Res Clin Pract*. 2008;80(3):473–476. [PubMed: 18359120]
88. Urakami T, Yoshida A, Suzuki J, et al. Differences in prevalence of antibodies to GAD and IA-2 and their titers at diagnosis in children with slowly and rapidly progressive forms of type 1 diabetes. *Diabetes Res Clin Pract*. 2009;83(1):89–93. [PubMed: 19019475]
89. Imkamp AK, Gulliford MC. Trends in type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991–2008. *Diabet Med*. 2011;28(7):811–814. [PubMed: 21395679]
90. Jarosz-Chabot P, Polanska J, Szadkowska A, et al. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. *Diabetologia*. 2011;54(3): 508–515. [PubMed: 21165594]
91. Skordis N, Efstathiou E, Kyriakides TC, et al. Epidemiology of type 1 diabetes mellitus in Cyprus: rising incidence at the dawn of the 21st century. *Hormones (Athens)*. 2012;11(1):86–93. [PubMed: 22450348]
92. Laron Z, Lewy H, Wilderman I, et al. Seasonality of month of birth of children and adolescents with type 1 diabetes mellitus in homogenous and heterogeneous populations. *Isr Med Assoc J*. 2005;7(6): 381–384. [PubMed: 15984382]
93. Kahn HS, Morgan TM, Case LD, et al. Association of type 1 diabetes with month of birth among U.S. youth: the SEARCH for diabetes in youth study. *Diabetes Care*. 2009;32(11):2010–2015. [PubMed: 19675199]
94. Weets I, Kaufman L, Van der Auwera B, et al. Seasonality in clinical onset of type 1 diabetes in Belgian patients above the age of 10 is restricted to HLA-DQ2/DQ8-negative males, which explains the male to female excess in incidence. *Diabetologia*. 2004;47(4): 614–621. [PubMed: 15298337]

95. Wandell PE, Carlsson AC. Time trends and gender differences in incidence and prevalence of type 1 diabetes in Sweden. *Curr Diabetes Rev.* 2013;9(4):342–349. [PubMed: 23721159]
96. Diaz-Valencia PA, Bougnères P, Valleron A-J. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. *BMC Public Health.* 2015;15(1):255. [PubMed: 25849566]
97. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. *Lancet.* 2008;371 (9626):1777–1782. [PubMed: 18502302]
98. Schober E, Waldhoer T, Rami B, Hofer B. Incidence and time trend of type 1 and type 2 diabetes in Austrian children 1999–2007. *J Pediatr.* 2009;155(2):190–3.e1. [PubMed: 19476954]
99. Haynes A, Bulsara MK, Bower C, Jones TW, Davis EA. Cyclical variation in the incidence of childhood type 1 diabetes in Western Australia (1985–2010). *Diabetes Care.* 2012;35:2300–2302. [PubMed: 22837374]
100. Derraik JG, Reed PW, Jefferies C, Cutfield SW, Hofman PL, Cutfield WS. Increasing incidence and age at diagnosis among children with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand). *PLoS One.* 2012;7(2):e32640. [PubMed: 22389717]
101. Sipetic S, Maksimovic J, Vlajinac H, et al. Rising incidence of type 1 diabetes in Belgrade children aged 0–14 years in the period from 1982 to 2005. *J Endocrinol Investig.* 2013;36(5):307–312. [PubMed: 23013910]
102. Bnuno G, Maule M, Biggeri A, et al. More than 20 years of registration of type 1 diabetes in Sardinian children: temporal variations of incidence with age, period of diagnosis, and year of birth. *Diabetes.* 2013;62(10):3542–3546. [PubMed: 23835336]
103. Lipman TH, Levitt Katz LE, Ratcliffe SJ, et al. Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia pediatric diabetes registry. *Diabetes Care.* 2013;36:1597–1603. [PubMed: 23340888]
104. Tran F, Stone M, Huang CY, et al. Population-based incidence of diabetes in Australian youth aged 10–18 yr: increase in type 1 diabetes but not type 2 diabetes. *Pediatr Diabetes.* 2014;15:585–590. [PubMed: 24636643]
105. Lawrence JM, Imperatore G, Dabelea D, et al. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the United States, 2002–2009. *Diabetes.* 2014;63:3938–3945. [PubMed: 24898146]
106. Patterson C, Gyürüs E, Rosenbauer J, et al. Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. *Diabetologia.* 2012;55(8): 2142–2147. [PubMed: 22638547]
107. Dahlquist G, Mustonen L, Group SCDS. Analysis of 20 years of prospective registration of childhood onset diabetes-time trends and birth cohort effects. *Acta Paediatr.* 2000;89(10):1231–1237. [PubMed: 11083381]
108. Gong C, Meng X, Saenger P, et al. Trends in the incidence of childhood type 1 diabetes mellitus in Beijing based on hospitalization data from 1995 to 2010. *Horm Res Paediatr.* 2013;80(5):328–334. [PubMed: 24216776]
109. Gyurus EK, Patterson C, Soltesz G. Twenty-one years of prospective incidence of childhood type 1 diabetes in Hungary--the rising trend continues (or peaks and highlands?). *Pediatr Diabetes.* 2012;13(1): 21–25. [PubMed: 22060160]
110. Cinek O, Kulich M, Sumnik Z. The incidence of type 1 diabetes in young Czech children stopped rising. *Pediatr Diabetes.* 2012;13: 559–563. [PubMed: 22487027]
111. Kraan JA, Claessen FMAP, Elliott KD, et al. Population based incidence of type 1 diabetes in New South Wales Australia 1990–2010-have we reached a plateau? (Oral abstract). *Pediatr Diabetes.* 2011; 12(suppl 15):14–39.
112. Fernández-Ramos C, Arana-Arri E, Jiménez-Huertas P, Vela A, Rica I. Incidence of childhood-onset type 1 diabetes in Biscay, Spain, 1990–2013. *Pediatr Diabetes.* 2017;18(1):71–76. [PubMed: 26782628]
113. Haynes A, Bulsara MK, Bower C, Jones TW, Davis EA. Regular peaks and troughs in the Australian incidence of childhood type 1 diabetes mellitus (2000–2011). *Diabetologia.* 2015;58(11):2513–2516. [PubMed: 26228717]

114. Furlanos S, Varney MD, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. *Diabetes Care*. 2008;31(8):1546–1549. [PubMed: 18487476]
115. Hemminki K, Li X, Sundquist J, Sundquist K. Familial association between type 1 diabetes and other autoimmune and related diseases. *Diabetologia*. 2009;52(9):1820–1828. [PubMed: 19543881]
116. Parkkola A, Harkonen T, Ryhanen SJ, Ilonen J, Knip M. Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. *Diabetes Care*. 2013;36(2):348–354. [PubMed: 23033245]
117. Olmos P, A'Hern R, Heaton DA, et al. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. *Diabetologia*. 1988;31(10):747–750. [PubMed: 3240835]
118. Harjutsalo V, Podar T, Tuomilehto J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. *Diabetes*. 2005;54(2):563–569. [PubMed: 15677516]
119. Steck AK, Barriga KJ, Emery LM, Fiallo-Scharer RV, Gottlieb PA, Rewers MJ. Secondary attack rate of type 1 diabetes in Colorado families. *Diabetes Care*. 2005;28(2):296–300. [PubMed: 15677782]
120. Gillespie KM, Aitken RJ, Wilson I, Williams AJ, Bingley PJ. Early onset of diabetes in the proband is the major determinant of risk in HLA DR3-DQ2/DR4-DQ8 siblings. *Diabetes*. 2014;63(3):1041–1047. [PubMed: 24203724]
121. Gillespie KM, Gale EA, Bingley PJ. High familial risk and genetic susceptibility in early onset childhood diabetes. *Diabetes*. 2002;51(1): 210–214. [PubMed: 11756343]
122. Green A, Schober E, Christov V, et al. Familial risk of type 1 diabetes in European children. *Diabetologia*. 1998;41(10):1151–1156. [PubMed: 9794100]
123. Dorman JS, Steenkiste AR, O'leary LA, McCarthy BJ, Lorenzen T, Foley TP. Type 1 diabetes in offspring of parents with type 1 diabetes: the tip of an autoimmune iceberg? *Pediatr Diabetes*. 2000;1(1): 17–22. [PubMed: 15016238]
124. El Hashimy M, Angelico MC, Martin BC, Krolewski AS, Warram JH. Factors modifying the risk of IDDM in offspring of an IDDM parent. *Diabetes*. 1995;44(3):295–299. [PubMed: 7883117]
125. Lorenzen T, Pociot F, Stilgren L, et al. Predictors of IDDM recurrence risk in offspring of Danish IDDM patients. Danish IDDM Epidemiology and Genetics Group. *Diabetologia*. 1998;41(6):666–673.
126. Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. *N Engl J Med*. 1984;311(3):149–152. [PubMed: 6738600]
127. Harjutsalo V, Lammi N, Karvonen M, Groop PH. Age at onset of type 1 diabetes in parents and recurrence risk in offspring. *Diabetes*. 2010;59(1):210–214. [PubMed: 19833881]
128. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet*. 2014;383(9922):1068–1083. [PubMed: 24315620]
129. Farsani SF, Van Der Aa M, Van Der Vorst M, Knibbe C, De Boer A. Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. *Diabetologia*. 2013;56(7):1471–1488. [PubMed: 23677041]
130. Fagot-Campagna A, Pettitt D, Engelgau M, et al. Type 2 diabetes among north American children and adolescents: an epidemiologic review and a public health perspective. *J Pediatr*. 2000;136:664–672. [PubMed: 10802501]
131. Reinehr T. Type 2 diabetes mellitus in children and adolescents. *World J Diabetes*. 2013;4(6):270–281. [PubMed: 24379917]
132. Delva J, O'Malley PM, Johnston LD. Racial/ethnic and socioeconomic status differences in overweight and health-related behaviors among American students: national trends 1986–2003. *J Adolesc Health*. 2006;39(4):536–545. [PubMed: 16982389]

133. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. *Nat Rev Endocrinol*. 2012;8(4):228–236.
134. Cizza G, Brown R, Rothe K. Rising incidence and challenges of childhood diabetes. A mini review. *J Endocrinol investig*. 2012;35(5): 541–546. [PubMed: 22572768]
135. Tattersall R. Maturity-onset diabetes of the young: a clinical history. *Diabet Med*. 1998;15(1):11–14. [PubMed: 9472858]
136. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. *Diabetes Care*. 2011;34(8):1878–1884. [PubMed: 21788644]
137. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *N Engl J Med*. 2001;345(13):971–980. [PubMed: 11575290]
138. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. *Diabetes*. 1975;24(1):44–53. [PubMed: 1122063]
139. Awa WL, Schober E, Wiegand S, et al. Reclassification of diabetes type in pediatric patients initially classified as type 2 diabetes mellitus: 15 years follow-up using routine data from the German/Austrian DPV database. *Diabetes Res Clin Pract*. 2011;94:463–467. [PubMed: 21955960]
140. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2014;37(suppl 1):S81–S90. [PubMed: 24357215]
141. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. *Diabetes Care*. 2015;38(7):1383–1392. [PubMed: 26106223]
142. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. *Nat Clin Pract Endocrinol Metab*. 2008;4(4):200–213.
143. Edghill EL, Dix RJ, Flanagan SE, et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. *Diabetes*. 2006;55(6):1895–1898. [PubMed: 16731860]
144. Iafusco D, Stazi MA, Cotichini R, et al. Permanent diabetes mellitus in the first year of life. *Diabetologia*. 2002;45(6):798–804. [PubMed: 12107723]
145. Rubio-Cabezas O, Minton JA, Caswell R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. *Diabetes Care*. 2009;32(1):111–116. [PubMed: 18931102]
146. Rubio-Cabezas O, Flanagan SE, Damhuis A, Hattersley AT, Ellard S. KATP channel mutations in infants with permanent diabetes diagnosed after 6 months of life. *Pediatr Diabetes*. 2012;13(4):322–325. [PubMed: 21981029]
147. Rubio-Cabezas O, Edghill EL, Argente J, Hattersley AT. Testing for monogenic diabetes among children and adolescents with antibody--negative clinically defined type 1 diabetes. *Diabet Med*. 2009;26(10): 1070–1074. [PubMed: 19900242]
148. Mohamadi A, Clark LM, Lipkin PH, Mahone EM, Wodka EL, Plotnick LP. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. *Pediatr Diabetes*. 2010;11 (3):203–207. [PubMed: 19686306]
149. Guillausseau PJ, Dubois-Laforgue D, Massin P, et al. Heterogeneity of diabetes phenotype in patients with 3243 bp mutation of mitochondrial DNA (maternally inherited diabetes and deafness or MIDD). *Diabetes Metab*. 2004;30(2):181–186. [PubMed: 15223991]
150. Laloi-Michelin M, Meas T, Ambonville C, et al. The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. *J Clin Endocrinol Metab*. 2009;94(8):3025–3030. [PubMed: 19470619]
151. Reardon W, Ross RJ, Sweeney MG, et al. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. *Lancet*. 1992;340(8832):1376–1379. [PubMed: 1360090]
152. van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrial tRNA(Leu) (UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. *Nat Genet*. 1992;1(5):368–371. [PubMed: 1284550]

153. Mazzaccara C, Iafusco D, Liguori R, et al. Mitochondrial diabetes in children: seek and you will find it. *PLoS One*. 2012;7(4):e34956. [PubMed: 22536343]
154. Rana M, Munns CF, Selvadurai H, Donaghue KC, Craig ME. Cystic fibrosis-related diabetes in children-gaps in the evidence? *Nat Rev Endocrinol*. 2010, 2010;6(7):371–378. [PubMed: 20498678]
155. Rana M, Munns C, Selvadurai H, et al., eds. Population-Based Incidence of CFRD in NSW and ACT, Australia. Orlando, FL: American Diabetes Association Meeting; 2010.
156. Hameed S, Morton JR, Jaffe A, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. *Diabetes Care*. 2010;33(2):221–226. [PubMed: 19910502]
157. Waugh N, Royle P, Craigie I, et al. Screening for cystic fibrosis-related diabetes: a systematic review. *Health Technol Assess*. 2012;16 (24):iii-iv):1–179.
158. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. *Diabetes Care*. 2009;32(9):1626–1631. [PubMed: 19542209]
159. Moran A, Milia C, Ducret R, Nair KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. *Diabetes*. 2001;50(6):1336–1343. [PubMed: 11375334]
160. Fowler C. Hereditary hemochromatosis: pathophysiology, diagnosis, and management. *Crit Care Nurs Clin North Am*. 2008;20(2):191–201. [PubMed: 18424348]
161. Tumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia major. *Pediatr Endocrinol Rev*. 2007;5 (2):642–648. [PubMed: 18084158]
162. Mitchell TC, McClain DA. Diabetes and hemochromatosis. *Curr Diab Rep*. 2014;14(5):488. [PubMed: 24682660]
163. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. *Diabetes Care*. 1991;14(suppl 4):39–47. [PubMed: 1748056]
164. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. *Neuropsychopharmacology*. 2007;32(4):765–772. [PubMed: 16823387]
165. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. *J Pediatr*. 1981;99(1):46–50. [PubMed: 6454771]
166. AI Uzri A, Stablein DM, Cohn A. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). *Transplantation*. 2001;72(6):1020–1024. [PubMed: 11579294]
167. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. *Transplantation*. 2001;72(10):1655–1661. [PubMed: 11726827]
168. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. *Transplantation*. 2002;73(3):379–386. [PubMed: 11884934]
169. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. *JAMA Psychiat*. 2013;70(10):1067–1075.
170. Amed S, Dean H, Sellers EA, et al. Risk factors for medication-induced diabetes and type 2 diabetes. *J Pediatr*. 2011;159(2):291–296. [PubMed: 21353243]
171. Bhisitkul DM, Morrow AL, Vinik AI, Shults J, Layland JC, Rohn R. Prevalence of stress hyperglycemia among patients attending a pediatric emergency department. *J Pediatr*. 1994;124(4):547–551. [PubMed: 8151468]
172. Valerio G, Franzese A, Carlin E, Pecile P, Perini R, Tenore A. High prevalence of stress hyperglycaemia in children with febrile seizures and traumatic injuries. *Acta Paediatr*. 2001;90(6):618–622. [PubMed: 11440092]
173. Gaugtitz GG, Herndon DN, Kulp GA, Meyer WJ 3rd, Jeschke MG. Abnormal insulin sensitivity persists up to three years in pediatric patients post-bum. *J Clin Endocrinol Metab*. 2009;94(5):1656–1664. [PubMed: 19240154]

174. Saz EU, Ozen S, Simsek Goksen D, Darcan S. Stress hyperglycemia in febrile children: relationship to prediabetes. *Minerva Endocrinol.* 2011;36(2):99–105. [PubMed: 21519318]
175. Weiss SL, Alexander J, Agus MS. Extreme stress hyperglycemia during acute illness in a pediatric emergency department. *Pediatr Emerg Care.* 2010;26(9):626–632. [PubMed: 20805780]
176. Herskowitz RD, Wolfsdorf JI, Ricker AT, et al. Transient hyperglycemia in childhood: identification of a subgroup with imminent diabetes mellitus. *Diabetes Res.* 1988;9(4):161–167. [PubMed: 3073902]
177. Schatz DA, Kowa H, Winter WE, Riley WJ. Natural history of incidental hyperglycemia and glycosuria of childhood. *J Pediatr.* 1989; 115(5 Pt 1):676–680. [PubMed: 2681635]
178. Vardi P, Shehade N, Etzioni A, et al. Stress hyperglycemia in childhood: a very high risk group for the development of type I diabetes. *J Pediatr.* 1990;117(1 Pt 1):75–77. [PubMed: 2196361]
179. Herskowitz-Dumont R, Wolfsdorf JI, Jackson RA, Eisenbarth GS. Distinction between transient hyperglycemia and early insulin-dependent diabetes mellitus in childhood: a prospective study of incidence and prognostic factors. *J Pediatr.* 1993;123(3):347–354. [PubMed: 8355109]
180. Bhisitkul DM, Vinik AI, Morrow AL, et al. Prediabetic markers in children with stress hyperglycemia. *Arch Pediatr Adolesc Med.* 1996;150 (9):936–941. [PubMed: 8790124]
181. Shehadeh N, On A, Kessel I, et al. Stress hyperglycemia and the risk for the development of type I diabetes. *J Pediatr Endocrinol Metab.* 1997;10(3):283–286. [PubMed: 9388819]



**TABLE 1****Criteria for the diagnosis of diabetes mellitus**

1. Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration $\geq 11.1$ mmol/L (200 mg/dL).
or
2. Fasting plasma glucose $\geq 7.0$ mmol/L ( $\geq 126$ mg/dL). Fasting is defined as no caloric intake for at least 8 h. <sup>a</sup>
or
3. Two-hour postload glucose $\geq 11.1$ mmol/L ( $\geq 200$ mg/dL) during an OGTT. <sup>a</sup>
The test should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water or 1.75 g/kg of body weight to a maximum of 75 g.
or
4. HbA1c $\geq 6.5\%$ <sup>b</sup>
The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.

<sup>a</sup>In the absence of unequivocal hyperglycemia, the diagnosis of diabetes based on these criteria should be confirmed by repeat testing.

<sup>b</sup>A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests. The role of HbA1c alone in diagnosing type 1 diabetes in children is unclear.

TABLE 2

## Etiological classification of diabetes

**I. Type 1**

$\beta$ -cell destruction, usually leading to absolute insulin deficiency

Immune mediated (characterized by presence of one or more autoimmune markers (IAA, GAD, IA-2, ZnT8)

Idiopathic

**II. Type 2**

Insulin resistance with relative insulin deficiency and subsequent hyperglycemia

**III. Other specific types**

A. Common forms of monogenic diabetes <sup>a</sup>	E. Drug- or chemical-induced
MODY	Insulin resistance and deficiency
HNF4-A MODY	Glucocorticoids
GCK-MODY	Nicotinic acid
HNF1A-MODY	Atypical antipsychotics
HNF1B-MODY	Protease inhibitors (first generation)
Neonatal diabetes	Statins
<i>KCNJ11</i>	Insulin deficiency
<i>INS</i>	$\beta$ -Blockers
<i>ABCC8</i>	Calcineurin inhibitors
6q24 ( <i>PLAGL1, HYMA1</i> )	Diazoxide
<i>GATA6</i>	Phenytoin
<i>EIF2AK3</i>	L-asparaginase
<i>FOXP3</i>	Pentamidine
	Thiazide diuretics
	Insulin resistance
	$\beta$ -adrenergic agonists
	Growth hormone
B. Genetic defects in insulin action	F. Infections
<i>INSR</i>	Congenital rubella
Congenital-generalized lipodystrophy	Enterovirus
Familial partial lipodystrophy	Cytomegalovirus

*PIK3R1* (Short Syndrome)

- C. Diseases of the exocrine pancreas
  - Pancreatitis
  - Trauma/pancreatectomy
  - Neoplasia
  - Cystic fibrosis-related diabetes
  - Hemochromatosis
  - Transfusion-related iron overload

- G. Uncommon forms of immune-mediated diabetes
  - Anti-insulin receptor antibodies
  - Polyendocrine autoimmune deficiencies APS I and II

## D. Endocrinopathies

- Acromegaly
- Cushing's syndrome
- Hyperthyroidism
- Phaeochromocytoma
- Glucagonoma
- Somatostatinoma

## H. Other genetic syndromes sometimes associated with diabetes

- Down syndrome
- Klinefelter syndrome
- Tumer syndrome
- Friedreich's ataxia
- Myotonic dystrophy
- Porphyria
- Prader-Willi syndrome

**IV. Gestational diabetes mellitus (GDM)**

Abbreviations: HNF1, hepatic nuclear factor; GCK, glucokinase.

<sup>a</sup>See also Monogenic Diabetes Chapter.

Clinical characteristics of type 1 diabetes, type 2 diabetes, and monogenic diabetes in children and adolescents

**TABLE 3**

Characteristic	Type 1	Type 2	Monogenic
Genetics	Polygenic	Polygenic	Monogenic
Age of onset	>6–12 mo	Usually pubertal (or later)	Often post pubertal except for GCK-MODY2 and neonatal diabetes (onset <6–12 mo)
Clinical presentation	Most often acute, rapid	Variable; from slow, mild (often insidious) to severe	Variable (frequently incidental in GCK-MODY2)
Associations			
Autoimmunity	Yes	No	No
Ketosis	Common	Rare	Common in neonatal diabetes, rare in other forms
Obesity	Population frequency	Increased frequency	Population frequency
Acanthosis nigricans	No	Yes	No
Frequency (% of all diabetes in young people)	Usually 90%+	Most countries <10% Japan 6096–80%	1–6%
Parent with diabetes	2–494	80%	90%+TF. <sup>a</sup>

<sup>a</sup>Mutations may occur de novo